Head-to-head data: PFVs, LNPs, and electroporation for nucleic acid delivery in cell engineering

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Head-to-head data: PFVs, LNPs, and electroporation for nucleic acid delivery in cell engineering

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

Can pre-formed vesicles (PFVs) deliver better outcomes than electroporation and lipid nanoparticles (LNPs) for nucleic acid delivery in cell engineering? This session presents head-to-head comparative data across delivery platforms, covering transfection efficiency, cell viability, yield, and scalability across T cell, NK cell, and other clinically relevant cell types.

Attendees will gain a practical framework for selecting the most appropriate delivery platform based on payload type, cell type, and manufacturing context, with data drawn from mRNA, CRISPR, and DNA delivery applications in both centralized and decentralized manufacturing settings.

Attend this Live30 to:

Review comparative data demonstrating greater than 80% knockout efficiency with PFVs versus electroporation, a more than 5-fold increase in edited T cell yield by day 10, and over 85% CAR+ T cells achieved with PFVs compared to approximately 40% with LNPs
Understand how PFVs support scalable, closed manufacturing workflows, including more than 80% TCR knockout efficiency in stirred-tank bioreactor systems and more than 30% stable gene insertion in primary human T cells using a fully non-viral approach
Evaluate practical criteria for selecting between PFVs, LNPs, and electroporation based on cell type, payload, and workflow requirements
Apply instrument-free, incubation-based PFV loading to reduce formulation complexity, shorten optimization cycles, and accelerate progression from research to clinic

Register now to gain data-driven insight into how PFVs can improve cell engineering outcomes and simplify manufacturing across a range of therapeutic applications.

Sai Arun Batra

Senior Scientist, Process Development Services at Sartorius

Dr. Sai Arun Batra is a Senior Scientist in Upstream Process Development at Sartorius in Marlborough, MA. He has a background in immunology, cell therapy, and process development, with experience spanning discovery, and process optimization. He earned his PhD from Washington State University and completed postdoctoral training at Baylor College of Medicine, where he worked on autologous CAR T-cell therapies. At Sartorius, his work focuses on scalable bioreactor-based workflows for gene editing, cell therapy, and advanced therapy manufacturing.

Nadia Mazzaro

Scientific Support Specialist at Sartorius

Dr. Nadia Mazzaro is a Scientific Support Specialist at Sartorius (Sartorius Polyplus® site in Illkirch, France) where she supports global customers in viral and non-viral in vivo gene delivery and bioproduction applications for advanced therapies. Her work focuses on scientific support, translational vector technologies, external collaborations, and internal R&D initiatives in gene and cell therapy. She earned her PhD in Neuroscience and Brain Technologies from the University of Genoa and began her career in gene therapy in the laboratory of Alberto Auricchio, working on AAV-based approaches for inherited retinal diseases. Her research experience includes positions at the Italian Institute of Technology, CNRS, and the Telethon Institute of Genetics and Medicine, with expertise spanning neurodegeneration, retinal diseases, AAV gene therapy, and in vivo genome editing.

In 39 Days

You have registered for this webinar